214 related articles for article (PubMed ID: 21375480)
41. Agmatine, by Improving Neuroplasticity Markers and Inducing Nrf2, Prevents Corticosterone-Induced Depressive-Like Behavior in Mice.
Freitas AE; Egea J; Buendia I; Gómez-Rangel V; Parada E; Navarro E; Casas AI; Wojnicz A; Ortiz JA; Cuadrado A; Ruiz-Nuño A; Rodrigues ALS; Lopez MG
Mol Neurobiol; 2016 Jul; 53(5):3030-3045. PubMed ID: 25966970
[TBL] [Abstract][Full Text] [Related]
42. Pramipexole is active in depression tests and modulates monoaminergic transmission, but not brain levels of BDNF in mice.
Schulte-Herbrüggen O; Vogt MA; Hörtnagl H; Gass P; Hellweg R
Eur J Pharmacol; 2012 Feb; 677(1-3):77-86. PubMed ID: 22206815
[TBL] [Abstract][Full Text] [Related]
43. Long-term adaptive changes induced by serotonergic antidepressant drugs.
Faure C; Mnie-Filali O; Haddjeri N
Expert Rev Neurother; 2006 Feb; 6(2):235-45. PubMed ID: 16466303
[TBL] [Abstract][Full Text] [Related]
44. The modulation of adult neuroplasticity is involved in the mood-improving actions of atypical antipsychotics in an animal model of depression.
Morais M; Patrício P; Mateus-Pinheiro A; Alves ND; Machado-Santos AR; Correia JS; Pereira J; Pinto L; Sousa N; Bessa JM
Transl Psychiatry; 2017 Jun; 7(6):e1146. PubMed ID: 28585931
[TBL] [Abstract][Full Text] [Related]
45. Therapeutic potential of serotonin 4 receptor for chronic depression and its associated comorbidity in the gut.
Agrawal L; Korkutata M; Vimal SK; Yadav MK; Bhattacharyya S; Shiga T
Neuropharmacology; 2020 Apr; 166():107969. PubMed ID: 31982703
[TBL] [Abstract][Full Text] [Related]
46. Beyond good and evil: A putative continuum-sorting hypothesis for the functional role of proBDNF/BDNF-propeptide/mBDNF in antidepressant treatment.
Diniz CRAF; Casarotto PC; Resstel L; Joca SRL
Neurosci Biobehav Rev; 2018 Jul; 90():70-83. PubMed ID: 29626490
[TBL] [Abstract][Full Text] [Related]
47. [Stress, depression and cerebral plasticity: an update of clinical and experimental findings].
Allilaire JF; Lôo H
Bull Acad Natl Med; 2005 May; 189(5):845-50; discussion 850-1. PubMed ID: 16433456
[TBL] [Abstract][Full Text] [Related]
48. The role of GSK-3 in treatment-resistant depression and links with the pharmacological effects of lithium and ketamine: A review of the literature.
Costemale-Lacoste JF; Guilloux JP; Gaillard R
Encephale; 2016 Apr; 42(2):156-64. PubMed ID: 26995153
[TBL] [Abstract][Full Text] [Related]
49. New drug targets in the signaling pathways activated by antidepressants.
Páez-Pereda M
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jul; 29(6):1010-6. PubMed ID: 15946780
[TBL] [Abstract][Full Text] [Related]
50. The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants.
Hill MN; Hillard CJ; Bambico FR; Patel S; Gorzalka BB; Gobbi G
Trends Pharmacol Sci; 2009 Sep; 30(9):484-93. PubMed ID: 19732971
[TBL] [Abstract][Full Text] [Related]
51. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
Gaetani S; Dipasquale P; Romano A; Righetti L; Cassano T; Piomelli D; Cuomo V
Int Rev Neurobiol; 2009; 85():57-72. PubMed ID: 19607961
[TBL] [Abstract][Full Text] [Related]
52. 5-HT(4) receptors, a place in the sun: act two.
Bockaert J; Claeysen S; Compan V; Dumuis A
Curr Opin Pharmacol; 2011 Feb; 11(1):87-93. PubMed ID: 21342787
[TBL] [Abstract][Full Text] [Related]
53. 5-HT7 receptor antagonists as a new class of antidepressants.
Mnie-Filali O; Lambás-Señas L; Zimmer L; Haddjeri N
Drug News Perspect; 2007 Dec; 20(10):613-8. PubMed ID: 18301795
[TBL] [Abstract][Full Text] [Related]
54. [Antidepressant drugs and central monoaminergic receptors].
Asakura M; Tsukamoto T
Yakubutsu Seishin Kodo; 1985 Dec; 5(4):303-19. PubMed ID: 2870595
[TBL] [Abstract][Full Text] [Related]
55. Physical activity and depression: Towards understanding the antidepressant mechanisms of physical activity.
Kandola A; Ashdown-Franks G; Hendrikse J; Sabiston CM; Stubbs B
Neurosci Biobehav Rev; 2019 Dec; 107():525-539. PubMed ID: 31586447
[TBL] [Abstract][Full Text] [Related]
56. Underlying mechanisms mediating the antidepressant effects of estrogens.
Osterlund MK
Biochim Biophys Acta; 2010 Oct; 1800(10):1136-44. PubMed ID: 19900508
[TBL] [Abstract][Full Text] [Related]
57. Functional Selectivity and Antidepressant Activity of Serotonin 1A Receptor Ligands.
Chilmonczyk Z; Bojarski AJ; Pilc A; Sylte I
Int J Mol Sci; 2015 Aug; 16(8):18474-506. PubMed ID: 26262615
[TBL] [Abstract][Full Text] [Related]
58. [New perspectives of the mechanism of action of antidepressants arised from genomic theory of depression].
Cereseto M; Ferrero A
Vertex; 2003; 14(51):30-5. PubMed ID: 12690407
[TBL] [Abstract][Full Text] [Related]
59. Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants.
Gorzalka BB; Hill MN
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1575-85. PubMed ID: 21111017
[TBL] [Abstract][Full Text] [Related]
60. Neuronal plasticity: a link between stress and mood disorders.
Calabrese F; Molteni R; Racagni G; Riva MA
Psychoneuroendocrinology; 2009 Dec; 34 Suppl 1():S208-16. PubMed ID: 19541429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
